Skip to main content
. 2013 Feb 13;21(6):703–714. doi: 10.1007/s12282-013-0444-8

Fig. 3.

Fig. 3

Forest plot of progression-free survival subgroup analysis by region and ethnicity. Subsets were prespecified in the analysis plan. Data from 18-months’ median follow-up. EVE everolimus, EXE exemestane, HR hazard ratio, PBO placebo, PFS progression-free survival